If you've ever looked into the insurance coverage or product labeling for a Continuous Glucose Monitor (CGM), you may have come across two confusing terms: adjunctive and non-adjunctive.

These labels determine whether a CGM can be used independently to make treatment decisions, and they directly affect Medicare and insurance coverage eligibility in the United States.

This guide breaks down the core differences in adjunctive vs non adjunctive CGM, helping patients, caregivers, and healthcare providers understand what this regulatory distinction means for real-world glucose management.

What Is Adjunctive CGM?

An adjunctive CGM is a continuous glucose monitor labeled for supplemental use only. Under FDA labeling rules, the CGM reading is treated as a reference point — not a standalone result for making treatment decisions.

Before adjusting an insulin dose, changing medication, or taking any treatment action, users must first verify the CGM reading with a traditional fingerstick blood glucose meter (BGM).

In short, an adjunctive CGM complements fingerstick testing but cannot replace it. You can use it to follow glucose trends and directional changes — but any treatment action still requires fingerstick confirmation first.

Most early-generation CGM devices carried adjunctive labels. This reflected the accuracy limitations of sensors at the time — they could show trends, but measurement errors were too significant to support independent clinical decisions.

What Is Non-Adjunctive CGM?

A non-adjunctive CGM — also called a therapeutic CGM — is a continuous glucose monitor that the FDA has cleared for making treatment decisions directly from sensor readings, without needing fingerstick confirmation.

The non adjunctive cgm meaning centers on independence in treatment decisions: patients can act directly on a CGM's real-time glucose reading without a mandatory fingerstick every time.

This applies to decisions like adjusting an insulin dose, modifying carbohydrate intake, or taking other corrective steps — all without pausing to confirm the reading with a fingerstick meter.

In December 2016, the FDA approved the Dexcom G5 Mobile as the first CGM in the United States to receive a non-adjunctive label, marking a pivotal moment in diabetes management.

Researchers Castle and Jacobs described this as a paradigm shift — one that moved CGM values beyond supplemental reference material and into the realm of independent clinical decision-making [1].

What Is The Difference Between Adjunctive And Non-Adjunctive CGM?

The table below summarizes the key differences in adjunctive vs non adjunctive CGM:

Dimension	Adjunctive CGM	Non-Adjunctive CGM
FDA Label Purpose	Supplemental reference; fingerstick confirmation required	Independent use for treatment decisions
Fingerstick Confirmation Required	Yes (before treatment)	Not required
Also Known As	—	Therapeutic CGM
Medicare Coverage Eligibility	Not eligible	Eligible
Representative Devices	Early Dexcom G4	Dexcom G6/G7, FreeStyle Libre 2/3

From a practical standpoint, non-adjunctive CGM significantly simplifies daily glucose management. There's no need to carry lancets and test strips at all times, and multiple daily fingersticks are largely eliminated.

For patients on intensive insulin therapy (IIT), this distinction has a meaningful impact on quality of life — fewer interruptions and a more seamless monitoring experience throughout the day.

It's worth noting that even with a non-adjunctive CGM, clinicians may still recommend a fingerstick check if the reading doesn't match your symptoms or if the device signal is unstable.

The Non-Adjunctive Use Of CGM: Clinical Evidence

The safety and effectiveness of the non adjunctive use of cgm has been validated through multiple clinical studies.

In 2017, Dr. Shapiro of NYU School of Medicine analyzed the FDA MAUDE adverse event database, identifying over 25,000 reports of CGM sensor inaccuracy between 2015 and 2016 [2].

Of those quantifiable discrepancies, 55% showed errors of 100 mg/dL or greater [2]. This finding served as a key safety signal during the early rollout of non-adjunctive labeling, pushing the industry toward higher sensor accuracy standards.

As CGM technology has continued to mature, large-scale clinical data now support the safety of non-adjunctive CGM. The 2023 ANSHIN study evaluated adults on intensive insulin therapy across multiple clinical settings.

Results showed that non-adjunctive CGM use was safe and effective: mean HbA1c decreased by 1.3% in type 1 diabetes patients and by 1.0% in both type 2 diabetes patients and those aged 65 and older [3].

Severe hypoglycemia events dropped from 67.3 per 100 person-years at baseline to just 17.0 per 100 person-years during the intervention period [3].

These findings confirm that, with modern sensor accuracy, the non-adjunctive use of cgm is not only safe but can meaningfully improve glycemic outcomes for patients.

Insurance And Medicare Coverage: Why The Label Matters

For patients in the United States, whether a CGM carries a non-adjunctive label has direct implications for insurance reimbursement.

Effective January 12, 2017, Medicare began covering non-adjunctive (therapeutic) CGMs as durable medical equipment (DME) [4].

Under CMS policy, a non-adjunctive CGM is defined as one that can be used to make treatment decisions without a separate BGM confirmation. Adjunctive devices do not qualify for this coverage.

This means that cgm brands and manufacturers seeking Medicare reimbursement must first obtain FDA non-adjunctive labeling — making the label a critical commercial milestone for device makers.

This policy requirement has indirectly driven advances in sensor accuracy across the entire cgm supplies industry, as manufacturers continue to meet the precision standards that non-adjunctive clearance demands.

In 2023, Medicare expanded CGM coverage to include people with type 2 diabetes who are not on insulin — a significant shift away from the historical assumption that CGM was primarily for insulin-dependent patients.

Current CGM Devices: Non-Adjunctive At A Glance

Here is an overview of widely available CGM devices and their regulatory status:

Device	Manufacturer	FDA Status	Wear Duration
Dexcom G7	Dexcom	Non-Adjunctive	10 Days
FreeStyle Libre 3	Abbott	Non-Adjunctive	14 Days
Medtronic Guardian 4	Medtronic	Non-Adjunctive	7 Days

Note: Guardian 4 is typically used within hybrid closed-loop insulin delivery systems rather than as a standalone CGM.

Patients outside the United States should note that regulatory frameworks vary by region and may differ from the FDA labeling system. When evaluating products from cgm suppliers, always check the approvals applicable to your local market.

For example, SIBIONICS CGM devices like the SIBIONICS GS3 are available in the European market as CE-certified products, featuring a 14-day continuous wear design with real-time glucose tracking and trend analysis.

Verdict

The difference between adjunctive vs non adjunctive CGM comes down to a single regulatory question: can the device support treatment decisions on its own?

Adjunctive devices serve as supplemental tools and require fingerstick confirmation. Non-adjunctive devices carry FDA clearance for independent use — and non-adjunctive labeling is a prerequisite for Medicare coverage in the United States.

As sensor accuracy continues to improve, most mainstream consumer CGM devices on the market today have reached non-adjunctive standards, offering people with diabetes a more convenient and comprehensive monitoring experience.

If you're evaluating SIBIONICS or any other CGM product, consider your region's regulatory requirements, device accuracy specs, and personal needs — and always make your final choice in consultation with a healthcare provider.

FAQ

Q: Is Every CGM Device Non-Adjunctive?

No. Non-adjunctive status is a distinct FDA designation that applies to specific cleared devices — it is not a default label for all CGMs on the market.

Many early-generation devices and some CGMs in certain markets remain adjunctive, meaning treatment decisions still require fingerstick confirmation before acting on the CGM reading.

Q: With A Non-Adjunctive CGM, Do You Still Need Any Fingersticks?

In most everyday situations, no. Clinical guidelines do recommend a fingerstick check if the CGM reading clearly doesn't match how you feel, or if the sensor signal is unreliable.

As always, follow the specific guidance of your healthcare provider when it comes to confirming glucose readings.

Q: Does An Adjunctive CGM Still Have Medical Value?

Yes. Even an adjunctive CGM delivers meaningful clinical value. Real-time trend data, high and low glucose alerts, and historical reports all help patients understand their glucose patterns and communicate more effectively with their care team.

The key difference is that treatment decisions — such as adjusting insulin doses — still require fingerstick confirmation before acting.

Q: Is Non-Adjunctive CGM Appropriate For All Diabetes Types?

The ANSHIN study found that the benefits of non-adjunctive CGM extended to people with type 1 diabetes, type 2 diabetes, and adults aged 65 and older [3].

Whether non-adjunctive CGM is right for you should be assessed by a qualified healthcare professional based on your individual health status and treatment plan.

References

[1] Castle JR, Jacobs PG. (2016). Nonadjunctive Use of Continuous Glucose Monitoring for Diabetes Treatment Decisions. Journal of Diabetes Science and Technology, 11(1), 146–147. https://pubmed.ncbi.nlm.nih.gov/26880390/
[2] Shapiro AR. (2017). Nonadjunctive Use of Continuous Glucose Monitors for Insulin Dosing: Is It Safe? Journal of Diabetes Science and Technology, 11(4), 833–838. https://pmc.ncbi.nlm.nih.gov/articles/PMC5588827/
[3] Chao C, Andrade SB, Bergford S, et al. (2023). Assessing non-adjunctive CGM safety at home and in new markets (ANSHIN). Endocrinology, Diabetes & Metabolism, 6(3), e414. https://pubmed.ncbi.nlm.nih.gov/36864014/
[4] Centers for Medicare & Medicaid Services. (2024). Glucose Monitor — Policy Article A52464. cms.gov. https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=52464

Disclaimer

This article is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

Author Information

This article was written by the SIBIONICS Professional Health Content Team. The author has years of research experience in CGM and diabetes management, helping users optimize their device experience through science-based practices.

Last Updated: April 30, 2026

Related Reading:

1.CGM GMI VS A1C: Which Number Actually Matters?
2.CGM VS BGM Reviews 2026: Which One Is Better?
3.Is CGM More Accurate Than Fingerstick: Answer Revealed!